Surveillance of Healthcare-associated Infections & Antimicrobial Resistance
Status
Conditions
Treatments
Details and patient eligibility
About
The aims of this project, called "Surveillance of Healthcare-associated infections & Antimicrobial Resistance", or "SHARE", are to 1) enhance laboratory capacity to detect emerging AMR patterns; 2) strengthen hospital epidemiology programs to use data to prevent, detect, and contain emerging AMR threats; 3) deploy study teams to answer critical public health surveillance questions, and 4) to build a national network of infection prevention and control (IPC) resources to prevent, detect, and contain emerging infectious disease threats
Full description
The World Health Organization (WHO) has declared antimicrobial resistance (AMR) one of the top 10 global public health threats facing humanity. AMR burden is higher in low-and-middle-income countries (LMICs) where, in recent decades, incidence and mortality from healthcare-associated infections (HAI) due to multidrug resistant organisms (MDRO) have dramatically increased. For example, neonatal sepsis is the third most common cause of neonatal deaths and multidrug-resistant Gram-negative bacteria are now the leading cause of sepsis among hospitalized neonates in south Asia and sub-Saharan Africa, including Botswana.1,2 One in three newborns with an MDRO bloodstream infection will die.3 In 2021, to respond to the global threat of AMR, U.S. Centers for Disease Control & Prevention (CDC) announced the launch of a global "network of networks" to tackle the problem of AMR and healthcare-associated infections (HAIs). The network, called "Global Antimicrobial Resistance Laboratory and Response Network", solicited funding applications; in December of 2021, Botswana was announced as recipient of a 5-year cooperative agreement following the successful application for funding for a comprehensive AMR surveillance project. The project was developed by investigators from Botswana-UPenn Partnership (BUP) in collaboration with Botswana's Ministry of Health & Wellness (MOHW) and the University of Botswana (UB).
Enrollment
Sex
Volunteers
Inclusion criteria
- hospital inpatient admission to participating wards.
Exclusion criteria
- diagnosis of a bleeding disorder
- platelet counts of <50,000
- diagnosis of coagulopathy
- presence of active bleeding
- inability to have a nares swab collected due to some other condition where nasal swabbing would be contraindicated
- inability to have a rectal swab collected due to some other condition where rectal swabbing would be contraindicated
Trial design
1,500 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Jonathan Mr Stryko, MED
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal